New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
TREMFYA ® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
SPRING HOUSE, PENNSYLVANIA, March 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to support a hypothesis that not all IL-23 inhibitors are the same by demonstrating a differentiated binding mechanism for TREMFYA® (guselkumab) from risankizumab. Findings show that guselkumab is able to dose-dependently bind to CD64+a myeloid cells,1 the predominant source of IL-23-driven inflammation in the gut.2,b Data comprise one of Janssen’s 22 oral and poster presentations at the 18th Congress of the European Crohn’s and Col...
Source: Johnson and Johnson - March 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
' I Need Antibiotics for My Bronchitis,' Your Patient Insists'I Need Antibiotics for My Bronchitis,' Your Patient Insists
Do you capitulate and prescribe an antibiotic for"bronchitis" or is there an alternative?Medscape Family Medicine (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 23, 2023 Category: Allergy & Immunology Tags: Family Medicine/Primary Care Clinical Case Source Type: news
Severe Asthma Patients on Ways Their Doctors Could Improve Treatment
Approximately 25 million people in the U.S. have asthma, according to the Asthma and Allergy Foundation of America. While that number shows how common the condition has become, the severe form is more rare. An estimate from a September 2021 study in the Journal of Asthma and Allergy found that about 9% of people with asthma meet the criteria for severe asthma.
Severe asthma comes with significantly more challenges than regular asthma. People with this condition tend to experience more symptoms, including increased activity limitations, greater prevalence of heart disease, and lower lung function. Even with high doses of in...
Source: TIME: Health - February 7, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Disease healthscienceclimate Source Type: news
From dizziness to dry skin - 5 warning signs of conditions to spot in elderly relatives
Spotting these warning signs could help prevent a loved one suffering a serious health condition, such as a heart attack, hypothermia, flu, bronchitis or pneumonia. (Source: Daily Express - Health)
Source: Daily Express - Health - December 22, 2022 Category: Consumer Health News Source Type: news
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population
SPRING HOUSE, PENNSYLVANIA, November 11, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER program (DISCOVER-1 and DISCOVER-2) evaluating TREMFYA® (guselkumab) in adult patients with active psoriatic arthritis (PsA), which showed that early skin and enthesitis responsesa,b predicted longer-term clinical response,c including disease remission, at week 52.1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor therapy approved in the U.S. for adults with moderate to severe plaque psoriasis (PsO) and adults with active PsA...
Source: Johnson and Johnson - November 11, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life
SPRING HOUSE, PENNSYLVANIA, November 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER-2 study that show early (week 8) clinical improvementsa of most measures (joint and skin disease, enthesitis and dactylitis) in adult patients with active psoriatic arthritis (PsA) treated with TREMFYA® (guselkumab) were associated with meaningful improvements in health-related quality of life (HRQoL) (measured by EQ-5D)b from year one (week 52) through year two (week 100).1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor th...
Source: Johnson and Johnson - November 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Omicron: Bronchitis may persist 'for weeks' post-infection - three clues in your cough
Experts have warned that some symptoms of the latest Omicron strains are more likely to persist for weeks, compared to previous subvariants. (Source: Daily Express - Health)
Source: Daily Express - Health - November 7, 2022 Category: Consumer Health News Source Type: news
New TREMFYA ® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis (UC) with inadequate responses to previous treatments. The data presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting show an overall clinical response rate of approximately 80 percent in patients who were randomized to TREMFYA® (guselkumab).Clinical responsea at weeks 12 or 24 of the study was ultimately achieved by 80.2 percent of patients who w...
Source: Johnson and Johnson - October 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Lupin inks pact to acquire two inhalation brands from Sunovion for USD 75 mn
The acquisition of these two brands will expand the company's inhalation product portfolio in the US and strengthen its presence in the respiratory therapy area while continuing to provide patients access to these important medicines, Lupin said in a statement. Brovana is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 20, 2022 Category: Pharmaceuticals Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Plastic bronchitis: a rare complication following a motor vehicle collision - Lee J, Stanley K, Lowe MC.
Plastic bronchitis, more appropriately termed chyloptysis, is a rare and potentially fatal condition caused by chylous coating of the airways. These cast coating can dislodge and become an obstructive mass in the patient's airway, necessitating rapid inter... (Source: SafetyLit)
Source: SafetyLit - October 3, 2022 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
First Randomized Controlled Study with RejuvenAir(R) for Chronic Bronchitis shows Clinically Significant Results
Metered Cryospray treats damaged airways enabling a rejuvenative healing response
BOSTON, Sept. 6, 2022 -- (Healthcare Sales & Marketing Network) -- CSA Medical, Inc., today announced results from the first randomized, controlled study of Metered Cryos... Devices, Drug Delivery, Interventional CSA Medical, Metered Cryospray, RejuvenAir, Chronic Bronchitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 6, 2022 Category: Pharmaceuticals Source Type: news
Air Pollution Kills Millions Every Year: Action Needed
The World Health Organization calls air pollution the “single biggest environmental threat to human health" and estimates that 99 percent of the world’s population live in locations that are above WHO thresholds designed to protect human health. . Credit: Malav Goswami/IPSBy Felix HorneSep 2 2022 (IPS) Tarik, age 42, lives in a village adjacent to a decades-old coal power plant in Bosnia and Herzegovina. On the day we visited, Bosnian cities were some of the most polluted places on Earth. Describing the devastating health toll the air pollution took each year on the village’s older residents he voiced his fear for hi...
Source: IPS Inter Press Service - Health - September 2, 2022 Category: International Medicine & Public Health Authors: Felix Horne Tags: Environment Global Headlines Health Source Type: news
